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Differences in GlycA and lipoprotein
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acute kawasaki disease from other febrile
illnesses in children
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Abstract
Background: Glycosylation patterns of serum proteins, such as α1-acid glycoprotein, are modified during an acute
phase reaction. The response of acute Kawasaki disease (KD) patients to IVIG treatment has been linked to sialic
acid levels on native IgG, suggesting that protein glycosylation patterns vary during the immune response in acute
KD. Additionally, the distribution and function of lipoprotein particles are altered during inflammation. Therefore,
the aim of this study was to explore the potential for GlycA, a marker of protein glycosylation, and the lipoprotein
particle profile to distinguish pediatric patients with acute KD from those with other febrile illnesses.
Methods: Nuclear magnetic resonance was used to quantify GlycA and lipoprotein particle classes and subclasses
in pediatric subjects with acute KD (n = 75), post-treatment subacute (n = 36) and convalescent (n = 63) KD, as well
as febrile controls (n = 48), and age-similar healthy controls (n = 48).
Results: GlycA was elevated in acute KD subjects compared to febrile controls with bacterial or viral infections,
IVIG-treated subacute and convalescent KD subjects, and healthy children (P <0.0001). Acute KD subjects had
increased total and small low density lipoprotein particle numbers (LDL-P) (P <0.0001) and decreased total high
density lipoprotein particle number (HDL-P) (P <0.0001) compared to febrile controls. Consequently, the ratio of
LDL-P to HDL-P was higher in acute KD subjects than all groups tested (P <0.0001). While GlycA, CRP, erythrocyte
sedimentation rate, LDL-P and LDL-P/HDL-P ratio were able to distinguish patients with KD from those with other
febrile illnesses (AUC = 0.789–0.884), the combinations of GlycA and LDL-P (AUC = 0.909) or GlycA and the LDL-P/
HDL-P ratio (AUC = 0.910) were best at discerning KD in patients 6–10 days after illness onset.
Conclusions: High levels of GlycA confirm enhanced protein glycosylation as part of the acute phase response in
KD patients. When combined with common laboratory tests and clinical characteristics, GlycA and NMR-measured
lipoprotein particle parameters may be useful for distinguishing acute KD from bacterial or viral illnesses in pediatric
patients.
Keywords: Kawasaki disease, Biomarkers, GlycA, Lipoprotein particle number
Abbreviations: ANC, Absolute neutrophil count; AUC, Area under the curve; CAA, Coronary artery aneurysm;
CATHGEN, CATHeterization GENetics registry; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; HDL-
C, High density lipoprotein cholesterol; HDL-P, High density lipoprotein particle number; IQR, Interquartile range;
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IVIG, Intravenous immunoglobulin; JUPITER, Justification for the use of statins in primary prevention: an intervention
trial; KD, Kawasaki disease; LDL-P, Low density lipoprotein particle number; NMR, Nuclear magnetic resonance;
PMN, Polymorphonuclear cells; PREVEND, Prevention of renal and vascular end-stage disease study; ROC, Receiver
operating characteristic; TG, Triglycerides; VLDL, Very low density lipoprotein; WBC, White blood cell count;
WHS, Womens Health Study
Background
Kawasaki disease (KD) is a self-limited vasculitis that
typically presents in young children as an acute illness
with fever and mucocutaneous changes [1, 2]. If KD is
incorrectly diagnosed or left untreated, coronary artery
aneurysms (CAA) may develop, predisposing KD pa-
tients to long-term cardiovascular complications includ-
ing myocardial ischemia and infarction [3, 4]. Therefore,
early diagnosis and treatment in the acute phase of the
disease with intravenous immunoglobulin (IVIG) are im-
portant to reduce the risk of CAA [5, 6]. Diagnosis of
KD, however, is challenging because the clinical signs
are shared by other childhood acute rash/fever illnesses
and there are no laboratory tests with sufficient specifi-
city or sensitivity for detection of KD [7]. Therefore,
additional biomarkers are needed to aid in diagnosis.
GlycA is a novel, nuclear magnetic resonance (NMR)-
measured marker of inflammation whose signal arises
from the carbohydrate side-chains of circulating proteins
[8]. Hence, GlycA is a composite biomarker that inte-
grates both the protein levels and glycosylation states of
the most abundant acute phase proteins in serum. GlycA
predicted adverse cardiovascular events in subjects in
the Women’s Health, JUPITER, PREVEND, CATHGEN
and Intermountain Heart Collaborative studies, inde-
pendent of traditional risk factors [9–13]. GlycA also
predicted incident diabetes in a population of apparently
healthy US women as well as in a large population of
men and women in the Netherlands [14, 15]. Elevated
GlycA was shown to be associated with disease activity
and coronary atherosclerosis in rheumatoid arthritis pa-
tients [16]. Little is known, however, about the levels of
this novel biomarker in acute pediatric illnesses such as
KD. Glycosylation patterns of serum and cell surface
proteins are critical determinants of the immune re-
sponse [17, 18], and response of acute KD patients to
IVIG treatment has been linked to sialic acid levels on
native IgG [19]. We, therefore, hypothesized that GlycA
levels are elevated in pediatric subjects with acute KD
and serve as an indicator of acute inflammation.
Recently we reported that pediatric and adult KD sub-
jects evaluated during the late convalescent phase of
their illness had a similar lipoprotein profile compared
to age-matched, healthy controls [20]. However, there
are specific changes in the distribution of lipoprotein
particle classes and subclasses in patients with active
chronic inflammatory disease [21, 22]. Therefore we
posited that the severe systemic inflammation that
occurs in acute KD modifies the lipoprotein particle dis-
tribution and that these alterations may serve as add-
itional markers of KD.
The aim of this study was to determine the ability of
GlycA concentrations and NMR lipoprotein particle
measures to distinguish pediatric patients with acute KD
from those with other febrile illnesses.
Methods
Study population
Subjects included 75 children diagnosed with KD
according to American Heart Association (AHA) criteria
and treated at Rady Children’s Hospital in San Diego,
CA between November 2005 and June 2011. Specimens
were obtained during 4 stages of KD: 1) pre-IVIG treat-
ment acute (2–10 days after start of illness; illness day 1
defined as first day of fever), and post-IVIG treatment 2)
subacute (13–24 days after start of illness), 3) early con-
valescent (25–75 days after start of illness) and 4) late
convalescent (9–49 months after start of illness). The
post-treatment subacute, early and late convalescent KD
samples were obtained from subjects enrolled during the
acute phase of illness. However, not all subjects provided
samples during each of the subsequent stages.
Coronary artery status for acute KD subjects was clas-
sified as dilated if the internal diameter normalized for
body surface area (Z score) was equal to or greater than
2.5 standard deviation units from the mean for the left
anterior descending or right coronary arteries assessed
by echocardiography during the first 6 weeks after dis-
ease onset. Aneurysms were defined as segments ≥1.5
times the diameter of the adjacent segments. Resistance
to IVIG treatment was defined as fever at ≥36 h after
the end of the IVIG infusion [7].
Forty-eight age-similar, healthy children undergoing
minor orthopedic surgical procedures and 48 febrile
children with acute illnesses of viral (adenoviral infec-
tion, influenza A or B, and viral syndrome) or bacterial
(scarlet fever, cutaneous abscess) origin were also in-
cluded in the study as healthy or febrile controls
(Table 1). Written informed consent and assent when
appropriate were obtained from the parents and sub-
jects, respectively. The protocol was approved by the
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Table 1 Clinical characteristics of pediatric untreated acute and IVIG-treated subacute and convalescent KD subjects and healthy and febrile controls
Characteristic Acute KD
2–10 days
(n = 75)
Subacute KD
13–24 days
(n = 36)
Early Convalescent
KD
25–75 days
(n = 43)
Late Convalescent
KD
9–49 months
(n = 20)
Acute Febrile
Controls
Bacterial origin
(n = 12)
Acute Febrile
Controls
Viral origin
(n = 36)
Healthy
Controls
(n = 48)
Male, n (%) 39 (52) 20 (56) 26 (60) 11 (55) 10 (83) 21 (58) –
Age, years 3.6 (1.8–5.0) 2.9 (1.7–4.6) 3.1 (1.7–4.5) 8.0 (6.7–9.2) 6.2 (4.7–8.2) 2.8 (1.6–5.3) 4.7 (3.0–6.6)
Illness day/month 6.0 d (4.5–7.0) 19 d (16–21) 48 d (34–55) 16 m (14–29) 3.5 d (3.0–4.3) 6.0 d (4.0–6.3) –
Median lab values
WBC, ×103/μL 13.7 (10.6–17.3) 7.3 (6.8–9.0) 7.4 (6.0–8.5) – 12.4 (10.1–14.5)# 8.7 (6.3–11.5)# –
PMN, % 56 (45–66) 37 (26–50) 37 (27–42) – 62 (46–70) 40 (23–54) –
ANC, cells/μL 9646 (6693–12,131) 3025 (1953–3950) 2516 (1823–3525) – 7014 (5565–9444) 3408 (2071–6764) –
ESR, mm/h 61 (47–75) 37 (31–57) 17 (9–31) – 31 (22–40)# 30 (17–39)# –
CRP, mg/dL 7.4 (4.7–16.7) 0.3 (0.3–0.8) 0.3 (0.3–0.3) – 2.2 (1.0–8.6)# 4.1 (2.2–5.0)# –
GlycA, μmol/L 808 (693–919) 440 (382–512) 309 (272–377) 341 (319–395) 595 (571–745) 611 (551–702) 319 (290–354)
Median (IQR = Interquartile Range; 25th-75th percentile); KD Kawasaki Disease, d days, m months, WBC white blood cell count, PMN polymorphonuclear cells, ANC absolute neutrophil count, ESR erythrocyte sedimenta-
tion rate, CRP C-reactive protein; GlycA, NMR-measured marker of systemic inflammation. #Lab data available for WBC 46 subjects, ESR 42 subjects, CRP 31 subjects
Acute KD samples were taken pre-IVIG treatment. All other KD samples were taken post-IVIG treatment
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Institutional Review Board at the University of California
San Diego.
Inflammatory markers
White blood cell count (WBC), absolute neutrophil
count (ANC), percent polymorphonuclear cells (PMN),
high sensitivity C-reactive protein (CRP), and erythro-
cyte sedimentation rate (ESR) were measured as part of
clinical care.
NMR analysis
NMR spectra were acquired from EDTA plasma samples
as previously described for the NMR LipoProfile® (lipopro-
tein particle) test at LipoScience (now Labcorp, Raleigh,
NC) [23]. The NMR Profiler platform is comprised of a
9.4T (400 MHz 1H frequency) spectrometer (Bruker Bios-
pin) with an integrated fluidics sample delivery system.
The GlycA signal was quantified as previously described
[8]. Lipoprotein particle profiles, triglycerides (TG) and
high density lipoprotein cholesterol (HDL-C) were quanti-
fied using the LipoProfile-3 algorithm. Briefly, lipoprotein
particle classes [very low density lipoprotein (VLDL), low
density lipoprotein (LDL) and high density (HDL)] and
subclasses [small, medium and large] were quantified
using the amplitudes of their spectroscopically distinct
lipid methyl group NMR signals [23]. Quantification of
TG and HDL-C was accomplished by converting NMR
particle numbers to lipid mass concentration units,
assuming that the lipoprotein particles have normal lipid
content. Previously published data showed that NMR-
derived TG and HDL-C values correlate well with chem-
ically measured values [23]. Samples were collected, stored
at −80 °C and run in batch in 2014. Stability of GlycA and
the lipoprotein analytes in frozen samples are stable for at
least 6.5 years when stored at −80 °C [8, 23].
Statistical analysis
Patient characteristics were summarized by group. Me-
dians and interquartile ranges (IQRs) were reported for
continuous variables, and frequency counts and percent-
ages were reported for categorical variables. One-way
ANOVA and Dunnet’s multiple comparison were used to
compare the differences between groups, and two-
tailed P values <0.05 were considered statistically sig-
nificant. Spearman rank correlation coefficients (r)
were calculated to evaluate interrelations between the
inflammatory markers and lipoprotein parameters,
and Mann–Whitney tests were used to gauge the sig-
nificance of the association. Statistical analyses were
performed using GraphPad Prism version 6. To assess
the performance of these biomarkers as potential
diagnostic tools, receiver operating characteristic
(ROC) areas under the curve (AUC), likelihood ratios,
positive predictive values, negative predictive values
and Wald (χ2) or z-statistics were calculated using
Excel Analyse-it® v3.9.01.
Results
Clinical characteristics of treatment naïve pediatric acute
KD subjects (n = 75) as well as IVIG-treated subjects
with subacute (13–24 days; n = 36), early convalescent
(25–75 days; n = 43) and late convalescent KD (9–49
months; n = 20), are described in Table 1 along with age-
similar healthy pediatric controls (n = 48) and pediatric
subjects with various acute febrile illnesses of bacterial
(n = 12) and viral (n = 36) origin. Although GlycA levels
were similar between healthy controls and convalescent
KD patients, levels were higher in children with acute
febrile illness and subacute KD than in healthy controls
(P <0.0001), or convalescent KD subjects (P <0.0001)
(Table 1, Fig. 1) and further elevated in acute KD
patients (P <0.0001). Approximately one third of the
subjects with acute KD had higher GlycA concentrations
than any of the febrile subjects with acute illness (Fig. 1).
GlycA concentrations were higher in subjects with acute
KD than in those with influenza A or B, scarlet fever or
viral syndrome (P <0.0001, 0.01 and 0.0001, respectively)
but not in subjects with abscesses or adenoviral infec-
tions (Additional file 1: Figure S1). GlycA levels did not
differ between acute KD patients who were resistant and
those who responded to IVIG treatment (Additional file
2: Figure S2) or between acute KD subjects with CAA or
dilated coronary arteries and those with normal echocar-
diograms (Fig. 1 and Additional file 2: Figure S2).
GlycA was strongly correlated with inflammatory
markers such as WBC (r = 0.43), ANC (r = 0.42) and
ESR (r = 0.42) (all P <0.001) and weakly correlated with
CRP (r = 0.26, P <0.05) in acute KD patients (Additional
file 3: Table S1). In addition, GlycA correlated strongly
with illness day (r = 0.48, P <0.0001), while CRP was
inversely correlated with this measure (r = −0.35, P <0.01)
(Additional file 3: Table S1).
Analysis of NMR-measured lipoprotein and lipid pa-
rameters revealed that TG and TG-rich lipoprotein par-
ticles (VLDL measures) did not differ between healthy
controls, pediatric KD patients and children with acute
febrile illness (Table 2). There were, however, notable
differences in HDL-P, LDL-P (Fig. 2a and b) and their
subclasses among the various groups. Acute KD sub-
jects and febrile controls had decreased HDL-C and
total HDL-P (P <0.0001). Acute KD subjects and chil-
dren with viral illnesses had decreased large HDL-P
(P <0.0001), while acute KD subjects and children with
bacterial illnesses had reduced small HDL-P (P <0.0001)
compared to healthy controls and convalescent KD sub-
jects (Table 2). Subjects with acute KD had higher total
and small LDL-P (P <0.0001) than subjects in other
groups. In addition, they had lower large LDL-P, leading
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to a reduction in weighted-average LDL size, compared to
all groups except those with acute febrile illness of viral
origin (data not shown). Subjects with subacute KD had
lipoprotein profiles between those of acute and convales-
cent illness, with HDL and LDL parameters nearing those
of healthy controls (Table 2). Subjects with subacute, early
and late convalescent KD had LDL-P/HDL-P ratios that
mirrored those of normal healthy controls (Table 2). The
LDL-P/HDL-P ratio was higher in acute KD subjects than
in the other six groups (P <0.0001), while no significant
differences were observed among healthy controls, sub-
acute and convalescent KD subjects, and febrile controls
(Fig. 2c).
To further explore the relationships between GlycA,
CRP, ESR and the ratio of LDL-P/HDL-P with time, we
plotted each biomarker as a function of illness day
(Fig. 3). CRP peaked on day 3 and trended downward to
approximately 50 % of peak levels by days 5–6, whereas
GlycA continued to rise until days 5–6 and remained
high through days 9–10 (Fig. 3a). Similar to GlycA, the
LDL-P/HDL-P ratio continued to rise until days 7–8
and remained high until after IVIG-treatment (Days 13–
15, Fig. 3b). ESR rose early and remained high, but
exhibited a high degree of variability (Fig. 3c and d).
Notably, GlycA and the LDL-P/HDL-P ratio appeared to
distinguish themselves from the other biomarkers be-
tween days 6 and 10.
A ROC analysis was performed to evaluate the relative
strengths of the NMR-measured biomarkers, CRP and
ESR, at differentiating acute KD from combined febrile
illness (bacterial and viral origin). The highest ROC
AUCs (95 % confidence intervals) were 0.789 (0.707–
0.872), 0.820 (0.721–0.918), 0.823 (0.752–0.894) and
0.884 (0.814–0.954) for the LDL-P/HDL-P ratio, CRP,
GlycA and ESR, respectively, for illness days 2–10. A
ROC analysis restricted to illness days 6–10 revealed
AUC values of 0.691 (0.556–0.826), 0.730 (0.587–0.873),
0.842 (0.732–0.952), O.864 (0.765–0.963), 0.879 (0.778–
0.979) and 0.891 (0.814–0.967), for total HDL-P, CRP,
the LDL-P/HDL-P ratio, total LDL-P, ESR and GlycA,
respectively (Additional file 4: Table S2). GlycA added to
total LDL-P or the LDL-P/HDL-P ratio, resulted in
AUCs (95 % confidence interval) of 0.909 (0.823–0.994)
and 0.910 (0.838–0.982), respectively (Additional file 4:
Table S2). The Wald test or z-statistics were 3.15, 6.09,
7.22, 7.37, 9.40, 9.99 and 11.65, and the positive likeli-
hood ratios were 8.89, 6.49, 14.15, 6.29, 16.51, 15.33 and
15.92 for CRP, the LDL-P/HDL-P ratio, total LDL-P,
Fig. 1 Plasma concentrations of GlycA (μmol/L) among patients with: acute, subacute, early and late convalescent KD patients, febrile controls of
bacterial and viral origin, and healthy controls. KD subjects are identified by coronary artery status: normal acute echocardiogram (solid black symbol);
CAA (open symbol); or dilated coronary artery (solid gray symbol). Horizontal bars represent median and interquartile range
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Table 2 Lipid profiles for pediatric untreated acute and IVIG-treated subacute and convalescent KD subjects and healthy and febrile pediatric controls
Characteristic Acute KD
2–10 days
(n = 75)
Subacute KD
13–24 days
(n = 36)
Early Convalescent KD
25–75 days
(n = 43)
Late Convalescent KD
9–49 months
(n = 20)
Acute Febrile Controls
Bacterial origin
(n = 12)
Acute Febrile Controls
Viral origin
(n = 36)
Healthy
Controls
(n = 48)
HDL-C, mg/dL 26 (19–33) 44 (39–47) 53 (48–58) 56 (52–65) 37 (32–41) 34 (28–39) 49 (42–54)
TG, mg/dL 78 (66–97) 104 (83–142) 79 (67–105) 68 (65–99) 86 (55–120) 63 (56–75) 93 (73–115)
LDL particles, nmol/L
Total LDL-P 1513 (1228–1826) 1259 (766–1416) 984 (680–1115) 861 (705–1167) 1186 (934–1273) 1052 (916–1231) 1110 (948–1248)
IDL-P 110 (65–159) 128 (56–176) 100 (44–143) 88 (63–118) 88 (65–117) 78 (55–107) 106 (71–145)
Large LDL-P 116 (29–244) 472 (261–629) 415 (281–497) 339 (290–527) 299 (216–340) 99 (47–215) 558 (426–718)
Small LDL-P 1230 (880–1574) 483 (392–677) 435 (331–532) 456 (291–536) 754 (549–973) 809 (688–996) 394 (190–531)
HDL particles, μmol/L
Total HDL-P 18 (14–22) 28 (27–32) 32 (30–34) 33 (32–35) 23 (22–24) 23 (20–27) 30 (27–34)
Large HDL-P 2.1 (1.4–3.1) 4.4 (3.3–5.4) 5.9 (4.6–7.6) 6.2 (4.8–8.5) 4.0 (2.8–6.2) 2.2 (1.3–3.2) 4.7 (3.8–5.8)
Medium HDL-P 8.6 (4.7–12.8) 11.4 (9.8–13.9) 11.7 (10.6–14.5) 12.4 (9.6–14.2) 12.9 (9.0–15.9) 10.2 (7.9–12.9) 9.1 (5.8–12.7)
Small HDL-P 6.8 (3.9–9.2) 11.8 (9.5–13.5) 13.6 (12.0–15.0) 13.9 (11.5–15.8) 4.5 (2.6–7.4) 10.5 (7.1–13.1) 16.2 (14.4–18.0)
VLDL particles, nmol/L
Total VLDL-P 39 (23–62) 56 (30–82) 36 (24–63) 31 (23–56) 57 (21–75) 27 (19–35) 49 (31–69)
Large VLDL-P 0.9 (0.6–1.7) 1.9 (1.2–5.0) 1.2 (0.8–2.1) 1.1 (0.6–1.4) 0.9 (0.4–1.5) 1.3 (0.9–1.5) 1.4 (0.9–2.8)
Medium VLDL-P 4.5 (1.8–10.4) 15.3 (7.3–28.7) 8.8 (3.2–16.5) 5.2 (0.6–1.4) 3.7 (2.5–18.2) 4.1 (2.0–8.1) 9.1 (4.6–19.4)
Small VLDL-P 31 (18–52) 29 (15–45) 31 (18–42) 26 (17–41) 46 (17–57) 19 (12–29) 35 (21–48)
LDL-P/HDL-P 92 (65–119) 41 (28–51) 29 (22–37) 27 (21–34) 50 (37–59) 45 (37–61) 38 (29–42)
Median (IQR = Interquartile Range; 25th-75th percentile). LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG triglycerides, LDL-P low density lipoprotein particle number, IDL-P inter-
mediate density lipoprotein particle number, HDL-P high density lipoprotein particle number, VLDL-P very low density particle number. Acute KD samples were taken pre-IVIG treatment. All other KD samples were
taken post-IVIG treatment
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Fig. 2 a) Total HDL-P, b) total LDL-P and c) the ratio of total LDL-P to total HDL-P among acute, subacute, early and late convalescent KD patients,
febrile controls of bacterial and viral origin, and healthy controls. Horizontal bars represent median and interquartile range
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ESR, GlycA plus total LDL-P, GlycA and GlycA plus
LDL-P/HDL-P, respectively (Additional file 4: Table S2).
A comparison of the ROC curves for all 6 biomarkers
can be found in Fig. 4.
Discussion
In this study, we identified changes in NMR-measured
lipoprotein particle parameters and GlycA that may be
useful in diagnosing acute KD or in monitoring resolution
of inflammation after treatment. GlycA levels were higher
in children with acute KD than in those with other febrile
illnesses. GlycA levels in acute KD subjects were also
higher than levels observed in subjects with chronic
inflammatory-mediated illnesses (e.g. cardiovascular dis-
ease, rheumatoid arthritis and systemic lupus erythemato-
sus) [9–16, 24]. In addition, lipoprotein particle class and
subclass numbers differed between patients with acute KD
and those with acute febrile illnesses. Several HDL-P mea-
sures were lower in acute KD patients than in healthy,
convalescent KD and febrile controls. Total LDL-P and
the ratio of LDL-P to HDL-P were higher in acute KD pa-
tients than in the other control groups. These changes are
consistent with previous observations that acute phase
proteins (e.g. α1-acid glycoprotein, serum amyloid A, ce-
ruloplasmin) and lipases (e.g. endothelial lipase, secreted
phospholipase A2-IIa and -V), which are upregulated dur-
ing inflammation, modify the size distribution and func-
tion of lipoprotein particles [25–29].
During acute inflammation, serum levels of CRP and
serum amyloid A (SAA) rise and fall within the first few
days [30]. In contrast, serum levels of the proteins that
give rise to the GlycA NMR signal (e.g. α1-acid glycopro-
tein, haptoglobin, α1-antitrypsin, α1-antichymotrypsin)
rise more slowly, reaching peak concentrations several
days after onset of an acute inflammatory reaction, and fall
slowly over weeks [30]. Our data support these observa-
tions, as CRP levels rose early and fell by day 6 while
GlycA levels rose later and remained high through day 10.
The finding that GlycA exhibited a strong correlation with
illness day, while CRP showed an inverse correlation con-
firms the results of the kinetic data. Therefore, GlycA and
CRP levels may add independent value when evaluating
patients with inflammatory illnesses such as KD; especially
6–10 days after illness onset when levels of these two bio-
markers varied in relation to one another.
The ROC AUCs of 0.910 and 0.909 for GlycA combined
with either the LDL-P/HDL-P ratio or LDL-P, respectively,
suggest that these biomarker combinations are better at
distinguishing KD from other febrile illnesses than CRP,
ESR or any of the 3 biomarkers alone. The results of the
Wald and Likelihood Ratio tests, alternative measures of
the performance of a diagnostic test, suggest that the com-
binations of GlycA with LDL-P/HDL-P or LDL-P will cor-
rectly distinguish patients with KD from those with febrile
illnesses more often than CRP or ESR alone. Thus, NMR-
measured biomarkers may be useful in determining
a b
c d
Fig. 3 Time course of biomarkers (median) in KD subjects from acute phase to early convalescence: a) GlycA (left y-axis; black line and symbols)
and CRP (right y-axis; dark gray line and symbols), b) LDL-P/HDL-P ratio (left y-axis; black line and symbols) and CRP (right y-axis; dark gray line and
symbols), c), GlycA (left y-axis; black line and symbols) and ESR (right y-axis; dark gray line and symbols), d) LDL-P/HDL-P ratio (left y-axis; black line
and symbols) and ESR (right y-axis; dark gray line and symbols) in KD patients plotted as a function of illness day (Illness day 1 = first day of fever).
Illness day 1 = first day of fever. Pre-IVIG treatment = days 2–10 and post-IVIG treatment = days 13–24
Connelly et al. BMC Pediatrics  (2016) 16:151 Page 8 of 11
antecedent inflammation in patients presenting later
(6–10 days) in the course of acute KD. These bio-
markers may also be useful in patients whose fever
and other mucocutaneous signs have resolved but for
whom subsequent periungual peeling prompts evalu-
ation for missed KD. Unfortunately we were unable
to test this hypothesis with our data, given that all
subjects with acute KD received IVIG-treatment by
10 days after fever onset. Therefore, future studies
with samples taken from patients untreated beyond
10 days of fever onset will more accurately determine
the kinetics of GlycA and LDL-P/HDL-P ratio as
markers of inflammation and will address the ques-
tion of whether or not these biomarkers will be useful
for missed KD.
When used along with the typical clinical characteris-
tics observed in patients with pediatric febrile illnesses
and standard diagnostic tools, the combination of GlycA
with either LDL-P or the LDL-P/HDL-P ratio may help
identify children with KD. GlycA has the advantage of
being a more stable biomarker, in terms of within-
subject biological variation, than CRP [8]. To illustrate
this point we determined the homeostatic set points, the
true values of analytes in biological homeostasis, for
CRP and GlycA in a cohort of normal, healthy, adult
volunteers (n = 23) collected for a previously published
biological variability study [8]. We calculated that 33
concurrent measurements of CRP would be required to
estimate its true value for a single patient, compared to
only one for GlycA [8, 31, 32]. In addition, while the
ESR is affected by IVIG treatment, GlycA is unaffected
by the presence of IgG [8] or IVIG [unpublished results].
Therefore, the combinations of GlycA with either LDL-
P/HDL-P or LDL-P are may provide an additional tool
for pediatric patient care.
We recognize both strengths and weaknesses in our
study. This is the first study to assess glycosylation
levels of plasma proteins in a well-characterized co-
hort of KD and febrile controls who share some clin-
ical features with acute KD patients. However, sample
size was limited and would need to be increased in
independent cohorts of pediatric subjects in order to
test the predictive value of these biomarkers in KD
diagnosis. In addition, the kinetic analysis suffered by
the limitation that the samples were not taken from
the same subjects at each time point. Finally, the
study would have benefited by the inclusion of add-
itional samples from patients with scarlet fever,
adenoviral infection and juvenile idiopathic arthritis
as these illnesses are most likely to cause clinical con-
fusion with KD. Therefore future studies will include
samples from these illnesses as well as serious ill-
nesses such as bacterial pneumonia, pyelonephritis
and sepsis.
Fig. 4 ROC curves for the discrimination of KD from febrile illnesses during illness days 6–10 by CRP, ESR, GlycA, LDL-P/HDL-P, GlycA and LDL-P/
HDL-P and GlycA + LDL-P
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Conclusions
High levels of GlycA confirm enhanced protein glycosyl-
ation as part of the acute phase response in KD patients.
When combined with common laboratory tests and clin-
ical characteristics, GlycA and NMR-measured lipopro-
tein particle parameters may be useful for distinguishing
acute KD from bacterial or viral illnesses in pediatric
patients.
Additional files
Additional file 1: Figure S1. Plasma concentrations of GlycA (μmol/L)
in subjects with: acute KD, abscess, adenoviral infection, influenza A or B,
scarlet fever or viral syndrome. ns = not statistically significant. Horizontal
bars represent median and interquartile range. (PPTX 70 kb)
Additional file 2: Figure S2. Plasma concentrations of GlycA (μmol/L)
in acute KD patients who responded to intravenous immunoglobulin
(IVIG) treatment, those who were IVIG-resistant, and healthy controls.
Noted are acute KD subjects with a normal echocardiogram (solid black
symbol) as well as those who developed a CAA (open symbol) or a
dilated coronary artery (solid gray symbol). ns = not statistically significant.
Horizontal bars represent median and interquartile range. (PPTX 58 kb)
Additional file 3: Table S1. Correlations among inflammatory markers
in acute KD subjects. (DOCX 15 kb)
Additional file 4: Table S2. SPerformance characteristics for GlycA,
lipoprotein parameters, CRP and ESR restricted to illness days 6-10. (DOCX 23 kb)
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